Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage
You may also be interested in...
Deals Of The Week: Sunovion/Elevation, Janssen/Genmab, Alnylam/Monsanto
With Roche’s Pascal Soriot set to become AstraZeneca’s CEO on Oct. 1, Soriot’s success in merging Genentech into Roche may open up AZ’s business development strategy to large-scale M&A.
Orchid’s Latest Sell-off To Hospira Leaves A Void To Fill
The Indian company has sold most of its injectables business to industry leader Hospira. What it does next to grow is a big question.
Hospira Hinges Emerging Market Success On Scale And Differentiation
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan